News related to Aranesp (Erythropoiesis Stimulating Protein) and/or conditions it is approved for
Aranesp Misbranding - Amgen Agrees $762 Million Payment
Source: Litigation / Medical Malpractice News From Medical News Today [2012.12.19]
After being found guilty of promoting off-label use of Aranesp (darbepoetin alfa), an anemia drug, Amgen Inc. agreed to pay $150 million in criminal fines and penalties. Prosecutors added that the company will also pay $612 in civil settlements. The settlement would include a payment to a former Aranesp product manager, Kassie Westmoreland, to resolve a whistleblower lawsuit...
FDA: New Warning for Procrit, Epogen, Aranesp
Source: MedicineNet epoetin alfa Specialty [2011.06.27]
Title: FDA: New Warning for Procrit, Epogen, Aranesp
Category: Health News
Created: 6/25/2011 11:01:00 AM
Last Editorial Review: 6/27/2011 12:00:00 AM
FDA approves extended dosing of Aranesp
Source: The Doctors Lounge - Hematology
FDA has approved every-3-week dosing of Aranesp (darbepoetin alfa) for treatment of chemotherapy - induced anemia.
|
